TIDMPRX

RNS Number : 3195Y

Proximagen Group PLC

29 February 2012

PROXIMAGEN GROUP PLC

("Proximagen" or "the Company")

Notification of Preliminary Results

London, UK, 29 February 2011 - Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system and inflammatory diseases, announces that it will issue its preliminary results for the twelve months ended 30 November 2011 on Monday 5 March 2012.

For further information please contact:

 
 Proximagen Group plc 
 Kenneth Mulvany, Chief Executive               Tel: +44 (0)20 
  Officer                                            7400 7700 
 James Hunter, Finance Director 
 
 Singer Capital Markets (Nominated 
  Adviser) 
 Shaun Dobson/Claes Spang                       Tel: +44 (0)20 
                                                     3205 7500 
 
 M:Communications (Media enquiries) 
 Mary-Jane Elliott / Mary Clark                 Tel: +44 (0)20 
  / Hollie Vile                                      7920 2330 
                                      proximagen@mcomgroup.com

About Proximagen

Proximagen Group plc (AIM:PRX) is a European biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and inflammation.

The Company is developing potential new best-in-class therapeutics in its core disease areas including epilepsy, Parkinson's disease, and Alzheimer's disease, as well as in other areas such as inflammation, oncology and neuropathic pain.

Proximagen has a number of existing partnerships with pharmaceutical companies including GlaxoSmithKline, Upsher-Smith and Lundbeck, and is developing a broad pipeline of drug candidate programmes, with four programmes in clinical development and more than ten earlier stage assets being progressed.

Proximagen's strategy is to advance its pipeline with its partners and to acquire innovative drug candidates that complement its pipeline, with the objective of scaling up its risk-mitigated operating model and generating sustainable profits.

For more information, please visit www.proximagen.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORTPMRTMBJTBIT

Proximagen Neuroscience (LSE:PRX)
Historical Stock Chart
From May 2024 to May 2024 Click Here for more Proximagen Neuroscience Charts.
Proximagen Neuroscience (LSE:PRX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Proximagen Neuroscience Charts.